Pierre G Coulie

Summary

Country: Belgium

Publications

  1. ncbi request reprint Human tumor-specific T lymphocytes: does function matter more than number?
    Pierre G Coulie
    Institute of Cellular Pathology, Universite Catholique de Louvain, Avenue Hippocrate 74, UCL 7459, B 1200 Brussels, Belgium
    Curr Opin Immunol 17:320-5. 2005
  2. pmc High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens
    Catherine Germeau
    Cellular Genetics Unit, Universite de Louvain, B 1200 Brussels, Belgium
    J Exp Med 201:241-8. 2005
  3. ncbi request reprint T-cell responses of vaccinated cancer patients
    Pierre G Coulie
    Cellular Genetics Unit, Christian de Duve Institute of Cellular Pathology, Universite de Louvain, Avenue Hippocrate 74, UCL 7459, B 1200 Brussels, Belgium
    Curr Opin Immunol 15:131-7. 2003
  4. pmc A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3
    P G Coulie
    Cellular Genetics Unit, Institute of Cellular Pathology, Cliniques Universitaires Saint Luc, Universite de Louvain, Brussels B1200, Belgium
    Proc Natl Acad Sci U S A 98:10290-5. 2001
  5. ncbi request reprint Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus
    Vaios Karanikas
    Cellular Genetics Unit, Institute of Cellular Pathology, Universite de Louvain, Brussels, Belgium
    J Immunol 171:4898-904. 2003
  6. ncbi request reprint Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen
    Pierre G Coulie
    Cellular Genetics Unit, Institute of Cellular Pathology, Universite de Louvain, Brussels, Belgium
    Immunol Rev 188:33-42. 2002
  7. ncbi request reprint Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2
    Wenbin Ma
    Ludwig Institute for Cancer Research, Brussels Branch, Avenue Hippocrate 74, UCL 7459, B 1200 Brussels, Belgium
    Int J Cancer 109:698-702. 2004
  8. doi request reprint Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities
    Thierry Connerotte
    de Duve Institute, Universite Catholique de Louvain, Department of Physiology and Immunology, Medical School of Vrije Universiteit Brussel, Brussels, Belgium
    Cancer Res 68:3931-40. 2008
  9. pmc Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen
    Christophe Lurquin
    Cellular Genetics Unit, Universite de Louvain, B 1200 Brussels, Belgium
    J Exp Med 201:249-57. 2005
  10. ncbi request reprint Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules
    Tomoko So
    Christian de Duve Institute of Cellular Pathology, Universite Catholique de Louvain, Avenue Hippocrate 74, UCL 7459, 1200 Brussels, Belgium
    Cancer Immunol Immunother 56:259-69. 2007

Collaborators

Detail Information

Publications34

  1. ncbi request reprint Human tumor-specific T lymphocytes: does function matter more than number?
    Pierre G Coulie
    Institute of Cellular Pathology, Universite Catholique de Louvain, Avenue Hippocrate 74, UCL 7459, B 1200 Brussels, Belgium
    Curr Opin Immunol 17:320-5. 2005
    ..Understanding how an efficient vaccine interferes with this coexistence is one of the current challenges of cancer immunotherapy...
  2. pmc High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens
    Catherine Germeau
    Cellular Genetics Unit, Universite de Louvain, B 1200 Brussels, Belgium
    J Exp Med 201:241-8. 2005
    ..Lurquin, C., B. Lethe, V. Corbiere, I. Theate, N. van Baren, P.G. Coulie, and T. Boon. 2004. J. Exp. Med. 201:249-257)...
  3. ncbi request reprint T-cell responses of vaccinated cancer patients
    Pierre G Coulie
    Cellular Genetics Unit, Christian de Duve Institute of Cellular Pathology, Universite de Louvain, Avenue Hippocrate 74, UCL 7459, B 1200 Brussels, Belgium
    Curr Opin Immunol 15:131-7. 2003
    ..However, a correlation between these T-cell responses and the tumor regressions has not yet been established. It appears that some patients display tumor regression with an unexpectedly low frequency of anti-vaccine T cells...
  4. pmc A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3
    P G Coulie
    Cellular Genetics Unit, Institute of Cellular Pathology, Cliniques Universitaires Saint Luc, Universite de Louvain, Brussels B1200, Belgium
    Proc Natl Acad Sci U S A 98:10290-5. 2001
    ..Even though they provide no information about the effector mechanisms responsible for the observed reduction in tumor mass in this patient, they would suggest that low-level CTL responses can initiate tumor rejection...
  5. ncbi request reprint Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus
    Vaios Karanikas
    Cellular Genetics Unit, Institute of Cellular Pathology, Universite de Louvain, Brussels, Belgium
    J Immunol 171:4898-904. 2003
    ..Taken together, our analysis of anti-MAGE-3.A1 T cell responses following peptide or ALVAC vaccination shows a degree of correlation between CTL response and tumor regression, but firm conclusions will require larger numbers...
  6. ncbi request reprint Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen
    Pierre G Coulie
    Cellular Genetics Unit, Institute of Cellular Pathology, Universite de Louvain, Brussels, Belgium
    Immunol Rev 188:33-42. 2002
    ..In 4/9 regressor patients and in 1/14 progressors we found a low level, usually monoclonal cytolytic T lymphocyte response against the MAGE-3 peptide...
  7. ncbi request reprint Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2
    Wenbin Ma
    Ludwig Institute for Cancer Research, Brussels Branch, Avenue Hippocrate 74, UCL 7459, B 1200 Brussels, Belgium
    Int J Cancer 109:698-702. 2004
    ..The CTL clones recognizing these 2 peptides also recognized allogeneic tumor cell lines expressing MAGE-C2 and HLA-A2. These 2 new peptides are the first known MAGE-C antigens and represent promising targets for cancer immunotherapy...
  8. doi request reprint Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities
    Thierry Connerotte
    de Duve Institute, Universite Catholique de Louvain, Department of Physiology and Immunology, Medical School of Vrije Universiteit Brussel, Brussels, Belgium
    Cancer Res 68:3931-40. 2008
    ....
  9. pmc Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen
    Christophe Lurquin
    Cellular Genetics Unit, Universite de Louvain, B 1200 Brussels, Belgium
    J Exp Med 201:249-57. 2005
    ..Naive T cells appear to be stimulated in the course of this process as new antitumor clonotypes arise after vaccination...
  10. ncbi request reprint Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules
    Tomoko So
    Christian de Duve Institute of Cellular Pathology, Universite Catholique de Louvain, Avenue Hippocrate 74, UCL 7459, 1200 Brussels, Belgium
    Cancer Immunol Immunother 56:259-69. 2007
    ..A24 CTL clones. These results suggest that peptide MAGE-A3(195-203) is poorly processed and is not an appropriate target for cancer immunotherapy...
  11. doi request reprint Comparison of stable human Treg and Th clones by transcriptional profiling
    Julie Stockis
    de Duve Institute, Universite Catholique de Louvain, Brussels, Belgium
    Eur J Immunol 39:869-82. 2009
    ..In conclusion, the hallmark of our panel of activated human Treg clones is to produce bioactive TGF-beta which has autocrine actions on Tregs and can have paracrine actions on other T cells...
  12. ncbi request reprint Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1
    Takeshi Hanagiri
    Christian de Duve Institute of Cellular Pathology, University of Louvain, Avenue Hippocrate 74, UCL 7459, 1200 Brussels, Belgium
    Cancer Immunol Immunother 55:178-84. 2006
    ..A1 CTL responses in melanoma patients with a tumor expressing gene MAGE-A3, we measured the blood frequency of anti-MAGE-3.A1 T cells in 45 patients, and found only two clear responses...
  13. ncbi request reprint Human T cell responses against melanoma
    Thierry Boon
    Ludwig Institute for Cancer Research, Brussels Branch, and Cellular Genetics Unit, Universite de Louvain, Brussels, Belgium
    Annu Rev Immunol 24:175-208. 2006
    ..In patients who do respond to the vaccine, the antivaccine T cells probably succeed in reversing focally this immunosuppression and trigger a broad activation of other antitumor T cells, which proceed to destroy the tumor...
  14. doi request reprint Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg
    Julie Stockis
    de Duve Institute, Universite Catholique de Louvain, Brussels, Belgium
    Eur J Immunol 39:3315-22. 2009
    ....
  15. doi request reprint Demethylation of the FOXP3 gene in human melanoma cells precludes the use of this epigenetic mark for quantification of Tregs in unseparated melanoma samples
    Sophie Lucas
    de Duve Institute, Universite Catholique de Louvain, Brussels, Belgium
    Int J Cancer 130:1960-6. 2012
    ..Our results imply that analyzing Treg frequencies by quantification of demethylated FOXP3i1 will require that tumor-infiltrating T cells be separated from melanoma cells...
  16. ncbi request reprint Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases
    Arcadi Cipponi
    de Duve Institute, Universite Catholique de Louvain, Bruxelles, Belgium
    Cancer Res 72:3997-4007. 2012
    ....
  17. doi request reprint Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?
    Arcadi Cipponi
    de Duve Institute, Universite Catholique de Louvain, Avenue Hippocrate 74, UCL 7459, 1200 Brussels, Belgium
    Cancer Immunol Immunother 60:1153-60. 2011
    ..In this context, we review results pertaining to TILs in human melanomas, their prognostic value, and some possible reasons why their presence could help in selecting melanoma patients for vaccination against tumor-specific antigens...
  18. pmc GARP is regulated by miRNAs and controls latent TGF-β1 production by human regulatory T cells
    Emilie Gauthy
    Welbio and de Duve Institute, Universite Catholique de Louvain, Brussels, Belgium
    PLoS ONE 8:e76186. 2013
    ..In transfected Th cells, the presence of this region decreased GARP levels, cleavage of pro-TGF-β1, and secretion of latent TGF-β1. ..
  19. doi request reprint Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
    Pierre G Coulie
    1 de Duve Institute and the Université catholique de Louvain, B 1200 Brussels, Belgium 2 WELBIO Walloon Excellence in Lifesciences and Biotechnology, B 1200 Brussels, Belgium
    Nat Rev Cancer 14:135-46. 2014
    ..These safety issues are even more of a concern for strategies targeting antigens that are not known to induce spontaneous T cell responses in patients. ..
  20. ncbi request reprint Cancer immunotherapy with MAGE antigens
    Pierre G Coulie
    Unité de Génétique Cellulaire, Universite Catholique de Louvain, Brussels, Belgium
    Suppl Tumori 1:S63-5. 2002
  21. ncbi request reprint A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes
    Francesca Schiavetti
    Cellular Genetics Unit, Christian de Duve Institute of Cellular Pathology, Universite de Louvain, B 1200 Brussels, Belgium
    Cancer Res 62:5510-6. 2002
    ..These results suggest that HERV-K-MEL is a source of antigens that are targeted by CTLs in melanoma patients and could therefore be used for vaccination...
  22. doi request reprint Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery
    Patrice Forget
    Department of Anesthesiology, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Brussels, Belgium
    Ann Surg Oncol 20:S650-60. 2013
    ..In cancer, nonsteroidal anti-inflammatory drugs (NSAIDs) could be of interest. We investigated the prognostic significance of NLR and the impact of intraoperative NSAIDs in cancer surgeries...
  23. ncbi request reprint Perioperative ketorolac in high risk breast cancer patients. Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial
    Patrice Forget
    Department of Anesthesiology, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Brussels, Belgium Electronic address
    Med Hypotheses 81:707-12. 2013
    ..In this paper, we describe the rationale, the preliminary analyses in our patients, the feasibility and the methodology of a prospective randomized trial called "Ketorolac in Breast Cancer trial" (KBCt) (NCT01806259). ..
  24. pmc Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12
    Shigui Zhu
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Immunother 35:680-8. 2012
    ..These results provide support for the use of these TCRs in cancer adoptive immunotherapy trials...
  25. doi request reprint [General principles and first clinical trials of therapeutic vaccines against cancer]
    Jean Francois Baurain
    Centre du Cancer, Cliniques Universitaires Saint Luc, Oncology Department, 54 Avenue Hippocrate, B 1200 Bruxelles, Belgique
    Bull Cancer 95:327-35. 2008
    ..Current research projects aim at elucidating the mechanisms of this resistance and to develop new vaccination strategies that circumvent this roadblock...
  26. ncbi request reprint Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide
    Danièle Godelaine
    Ludwig Institute for Cancer Research, Brussels Branch, Brussels, Belgium
    J Immunol 171:4893-7. 2003
    ..This polyclonality contrasts with the monoclonality of the CTL responses observed in patients vaccinated with MAGE-3.A1 peptide or with an ALVAC recombinant virus coding for this antigenic peptide...
  27. ncbi request reprint Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen
    Pierre Yves Dietrich
    Division of Oncology, Laboratory of Tumor Immunology, University Hospital, Geneva, Switzerland
    J Immunol 170:5103-9. 2003
    ..1-bearing TCRs, whereas functional outcomes result from the sum of these with other interactions between pMHC complex and TCR...
  28. ncbi request reprint Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells
    Nicolas van Baren
    Ludwig Institute for Cancer Research, 74 avenue Hippocrate, UCL7459, B 1200 Brussels, Belgium E mail
    J Clin Oncol 23:9008-21. 2005
    ....
  29. ncbi request reprint Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR
    Joannes F M Jacobs
    Department of Pediatric Hemato Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Int J Cancer 120:67-74. 2007
    ..Some rhabdomyosarcomas express several of these genes at high levels. Ewing's sarcomas have an overall low CGG expression...
  30. ncbi request reprint A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma
    Mitsuhiro Takenoyama
    Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807 8555, Japan
    Int J Cancer 118:1992-7. 2006
    ..These results strengthened the notion that unique tumor-specific antigens are highly represented not only in melanoma but also in other types of tumors, like nonsmall cell lung cancer...
  31. ncbi request reprint Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules
    Eric M Bluman
    Department of Orthopaedic Surgery, Brown University, Providence, Rhode Island, USA
    J Orthop Res 25:678-84. 2007
    ..These results suggest that immunotherapy targeted against chondrosarcoma cells is possible...
  32. pmc Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway
    Faten El Hage
    Institut National de la Sante et de la Recherche Medicale, Unité 753, Laboratoire Immunologie des Tumeurs Humaines, Villejuif, France
    Proc Natl Acad Sci U S A 105:10119-24. 2008
    ..This new epitope is, therefore, a promising candidate for cancer immunotherapy...
  33. ncbi request reprint Monoclonal and recombinant antibodies with T cell receptor-like reactivity
    Andreas Ziegler
    Institut für Immungenetik, Humboldt Universitat zu Berlin, Charite Campus Virchow Klinikum, Germany
    Recent Results Cancer Res 176:229-41. 2007
    ....
  34. ncbi request reprint A major histocompatibility complex-peptide-restricted antibody and t cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3
    Martin Hülsmeyer
    Institut für Chemie Kristallographie, Freie Universitat Berlin, 14195 Berlin, Germany, Cellectis, 93235 Romainville, France
    J Biol Chem 280:2972-80. 2005
    ..The HLA-A1.MAGE-A1.antibody structure is discussed in comparison with those of natural ligands recognizing HLA.peptide complexes...